AcelRx Pharmaceuticals Inc. (Nasdaq: ACRX) reported positive results from a Phase 3 study of ARX-04 to treat moderate to severe acute pain in post-operative study patients sending the stock price up 32 cents to close at $3.60.
AcelRx reports positive study results
September 15, 2016 at 17:14 PM EDT
